Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
8,764 EUR | +3,08 % |
|
-1,53 % | -20,18 % |
Resumen de negocios
Las ventas netas se distribuyen geográficamente de la siguiente manera: Japón (28,8%), América (34,5%) y otros (36,7%).
Número de empleados: 14 484
Ventas por actividad
JPY en millones | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 1 518 619 | 100,0 % | 1 603 672 | 100,0 % | +5,60 % |
Ventas por región
JPY en millones | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
United States
41,3
%
| 652 441 | 43,0 % | 663 108 | 41,3 % | +1,63 % |
Established Markets
25,9
%
| 358 407 | 23,6 % | 415 567 | 25,9 % | +15,95 % |
Japan
16,8
%
| 262 303 | 17,3 % | 270 126 | 16,8 % | +2,98 % |
International
9,9
%
| 144 735 | 9,5 % | 159 073 | 9,9 % | +9,91 % |
Greater China
5,5
%
| 80 011 | 5,3 % | 88 503 | 5,5 % | +10,61 % |
Other
0,5
%
| 20 722 | 1,4 % | 7 295 | 0,5 % | -64,80 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01/04/86 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 01/11 |
Kenji Yasukawa
CHM | Chairman | 64 | 01/04/86 |
Compliance Officer | - | 01/10/22 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 01/09/06 | |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01/06/16 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/04/83 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 01/06/21 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 01/06/17 |
Kenji Yasukawa
CHM | Chairman | 64 | 01/04/86 |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01/06/16 |
Haruko Shibumura
BRD | Director/Board Member | 59 | 01/06/19 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01/04/83 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 01/06/18 |
Hiroshi Kawabe
BRD | Director/Board Member | 72 | 01/06/19 |
Mika Nakayama
BRD | Director/Board Member | - | - |
Compliance Officer | - | 01/10/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 1 809 663 075 | 1 788 620 803 ( 98,84 %) | 16 561 000 ( 0,9151 %) | 98,84 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
7 266 342 | 3.89% | 24 923 553 $ | |
8 333 333 | 8.59% | 24 916 666 $ | |
ASTELLAS PHARMA INC. 0.04% | 731 000 | 0.04% | 7 203 245 $ |
FIBROGEN, INC. 4.99% | 4 968 367 | 4.99% | 5 962 040 $ |
ONCOLYS BIOPHARMA INC. 3.47% | 727 200 | 3.47% | 3 040 314 $ |
Información de la empresa
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.com![Dirección Astellas Pharma Inc.(YPH)](https://cdn.zonebourse.com/static/address/437689.png)
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Astellas BV
![]() Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Ventas por región
![Consenso](/images/consensus_flch.gif)
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+51,63 % | 796 mil M | |
+41,51 % | 628 mil M | |
-5,10 % | 358 mil M | |
+19,90 % | 331 mil M | |
+9,95 % | 301 mil M | |
+17,66 % | 244 mil M | |
+3,39 % | 228 mil M | |
+10,75 % | 214 mil M | |
+6,99 % | 165 mil M |
- Bolsa de valores
- Acciones
- Acción 4503
- Acción YPH
- Empresa Astellas Pharma Inc.